# Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

> **NCT07457580** · — · RECRUITING · sponsor: **Sanofi** · enrollment: 60 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Teplizumab

## Key facts

- **NCT ID:** NCT07457580
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07457580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07457580, "Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07457580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*